TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering
WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced…
